An Open-label, Prospective, Multi-center, Single-arm Study to assess the efficacy and safety of Adjuvant Osimertinib in Non-small Cell Lung Cancer (NSCLC) with Uncommon Epidermal Growth Factor Receptor Mutations (EGFRm)
Non-small Cell Lung Cancer
18 Years - 130 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Verified 01 Sept 2023 by AstraZeneca
This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.
No locations available
Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.